In patients with schizophrenia, adjunctive treatment with the DAO inhibitor sodium benzoate was effective against a range of symptom domains, including cognition, in a small 6 week randomized clinical trial (Lane et al., 2013). The gene discussed is DAO; the disease is schizophrenia.